C oronary heart disease is associated with intravascular platelet activation.1-3 Percutaneous transluminal coronary angioplasty (PTCA) is one established therapy for patients with localized coronary stenosis as an alternative to bypass surgery. The success of this intravascular dilatation technique is limited either by reocclusion or high-grade restenosis occurring early after dilatation and by long-term restenosis. Complications may be caused by a preexistent prethrombotic state or by activation of the hemostatic system by the PTCA maneuver itself. There is still a diagnostic gap, because no predictive laboratory test has been established to identify patients at increased risk. With singleplatelet flow cytometry (SPFC), it is possible to detect in vivo platelet activation in individual patients after staining platelet samples for thrombospondin-, CD62-, and CD63-related antigens that are exposed after activation. [4] [5] [6] [7] [8] [9] With this technique, this study was intended to clarify whether platelet activation is related to the early clinical outcome after elective PTCA.
Methods

Subjects and Study Design
Patients with proven coronary heart disease (CHD, n = 102) admitted to the University Clinic of Duesseldorf for elective PTCA were consecutively recruited when a high-grade coronary vessel stenosis of >85% was confirmed by visual analysis of the recent angiographic record. None of the recruited patients showed unstable angina. Patients with acute infarctions, hematological diseases, and diabetes mellitus were excluded. No exclusions were made for medication. Except for those with contraindications, all patients received acetylsalicylic acid (ASA) and calcium channel blockers at least 1 day before PTCA. Basic clinical characteristics and pretreatment are shown in Table 1 .
On the day of PTCA, a blood sample was taken for platelet activation marker analysis, and the patient was classified as having an "activated" or "nonactivated" platelet status. The classification result was not for- 
Blood Sampling
After the patient fasted overnight, venous blood was taken without tourniquet from resting subjects directly into platelet-stabilizing reagent (134 mmol/L EDTA, 0.7% hydroxychloroquine sulfate, 20 units/mL heparin; ratio, 9 volumes blood plus 1 volume reagent). Thereafter, the sample was immediately fixed with paraformaldehyde6J13 (0.5%, pH=7.4).
Antibodies
The monoclonal antibodies P10, 2.17, and 2. Table 2 .
All patients had generalized caliber irregularities of the dilated vessel, but only a minor fraction showed significant stenosis distal to the dilated area ( Table 1) . None of these developed acute ischemic episodes. During the PTCA procedure, one patient developed intermittent vasospastic vessel occlusion, and mural thrombosis was suspected in another patient (both from the activated subgroup), but none of these developed ischemic episodes. Visible endothelial dissection was observed in both groups, activated and nonactivated patients, to a similar extent (Table 1 ) and occurred in three of those six patients with verified post-PTCA acute ischemic events (Table 2) .
A nonactivated platelet status before PTCA was found in 56 patients (54.9%), and 46 patients (45.1%) were classified as activated ( Figure 1 ). All six postprocedural ischemic events occurred in patients from the activated group showing the highest levels of markerpositive platelets (Table 2 ; prevalence, six of 46, or 13%). However, no ischemic episode was found in the nonactivated group (prevalence, 0 of 56, or 0%; Figure  2) . The difference between the two patient groups is significant (p=0.007).
Since (3-blocker medication was apparently more frequent in the nonactivated group, the statistical analysis was also performed in the subset of patients who received no 3-blockers (n=40). In 24 of these patients, the platelet status was activated and the prevalence of post-PTCA ischemic events increased to 25% in this group (n=6), whereas no ischemic event was found in the patients with nonactivated platelets (p=0.035; Figure 2B) tion, or PTCA characteristics) were equally distributed between the study subgroups and those patients who subsequently suffered from documented occlusion and high-grade restenosis10, 17, 2425 (Tables 1 and 2 ). However, there was a dominance of dilated left anterior descending coronary artery (LAD) among those patients with post-PTCA ischemic episodes compared with the frequency of LAD dilatation in the cohort.
It must be admitted that the study design does not rule out the possibility that clinically silent vessel restenosis/occlusion occurred, because second-look angiography after 24 Our study aimed to show an association between platelet activation and post-PTCA ischemic events. Although not valid for definitive evaluation because of the small numbers of primary study end points, the data base presented allows an estimate of the expected sensitivity and specificity of the activation marker test with regard to acute post-PTCA ischemic events (Figure 2A) Several conclusions may be drawn. 1) Platelet activation marker analysis provides predictive information on the incidence of occlusive vascular complications after angioplasty. 2) In view of the significance of acute post-PTCA occlusion for morbidity and mortality,10,17-20,22,23,34 testing of all patients before an elective PTCA for the purpose of a thrombotic risk assessment might be considered. However, such a general recommendation can be made only after further confirmation of the study results presented.
